GLP-1 News — Week of November 9, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
FDA adds rare sudden vision loss warning to labels for GLP-1 drugs
The U.S. Food and Drug Administration is requiring a new warning about a rare form of sudden, severe vision loss to be added to prescribing information for all GLP-1 drugs used for obesity, diabetes, and related conditions. After reviewing more than 125 clinical trials, the agency estimated the event occurs in roughly 6 out of every 100,000 people treated for at least a year, and is updating Medication Guides and safety communications accordingly. (2026-11-10)
What this means for you: If you are on a GLP-1 and notice abrupt vision changes or vision loss, you should treat it as an emergency and seek immediate care. Your prescriber and pharmacist are likely to spend more time reviewing eye related risks and what symptoms to report at upcoming visits or refills, but the absolute risk remains very low for most patients.
Source: Associated Press
Related on Metabolic Ledger: /regulatory/glp1-long-term-safety
Wegovy pill use passes 3 million as Novo readies oral Ozempic launch
Novo Nordisk reported that U.S. prescriptions for its oral Wegovy formulation have exceeded 3 million, with about one prescription filled every five seconds. The company also said that new Ozempic oral tablets for adults with type 2 diabetes will be available in the U.S. soon, replacing discontinued Rybelsus doses as the branded oral semaglutide option for diabetes. (2026-11-06)
What this means for you: If you prefer pills over injections, it is getting easier to access oral semaglutide, but plan for possible insurance changes and new prior authorization requirements as Rybelsus is phased out. If you currently take Rybelsus, you should talk with your prescriber and insurer about switching to the new Ozempic tablets, how your dose will convert, and what your copay will be.
Source: Novo Nordisk
Related on Metabolic Ledger: /drugs/rybelsus-vs-wegovy
CagriSema beats tirzepatide on weight loss in phase 3 REIMAGINE 5 trial
Novo Nordisk announced topline phase 3 data from REIMAGINE 5 and REDEFINE 9 showing that once weekly CagriSema, a combination of cagrilintide and semaglutide, produced greater weight loss than tirzepatide 5 milligrams at a relatively low 1.0 mg/1.0 mg CagriSema dose. The company expects regulatory decisions from the FDA and Health Canada in the fourth quarter of 2026, positioning CagriSema as a potential next generation obesity and type 2 diabetes treatment. (2026-11-11)
What this means for you: Nothing about your current prescriptions changes yet, but if you have plateaued on semaglutide or tirzepatide, CagriSema could become another option in late 2026 or 2027. You may want to watch for approval decisions and, if you see an obesity or diabetes specialist, ask whether CagriSema trials or future formularies might fit your long term plan.
Source: Novo Nordisk
Related on Metabolic Ledger: /drugs/cagrisema
Novo previews ObesityWeek 2026 data on CagriSema and semaglutide in obesity related conditions
Ahead of the ObesityWeek 2026 meeting, Novo Nordisk outlined 26 abstracts that will feature new data on investigational CagriSema and on semaglutide in multiple obesity related diseases. The planned presentations focus on weight loss, metabolic outcomes, and potential organ specific benefits, highlighting how GLP-1 based therapies are being studied beyond simple weight change. (2026-10-29)
What this means for you: These conference results will not change what you can get at the pharmacy right now, but they will shape how specialists talk about long term GLP-1 use and future combination drugs. If you see an obesity medicine clinician, you may soon hear more detailed discussions of organ health benefits and chances to join trials of next wave treatments.
Source: Novo Nordisk
Related on Metabolic Ledger: /drugs/glp1-clinical-trials-explained
FDA advances proposal to bar bulk semaglutide, tirzepatide, and liraglutide from 503B compounding
The FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, which would prevent large outsourcing facilities from compounding these drugs from bulk active pharmaceutical ingredients. The agency says it sees no clinical need for bulk compounding now that branded GLP-1 supplies have largely stabilized, and it continues to cite safety and quality risks with mass marketed compounded alternatives. (2026-04-30)
What this means for you: If you rely on cheaper compounded GLP-1 injections from a large facility, you should plan for the possibility that this route could be sharply limited or shut down by 2027. It is wise to start discussing with your prescriber how you would transition to brand name products or other options if your current compounded source is no longer allowed to operate in the same way.
Source: FDA
Related on Metabolic Ledger: /regulatory/503a-vs-503b-glp1
Rybelsus tablets listed as to be discontinued as FDA shortage data show shift to Ozempic pills
An updated GLP-1 shortage tracker based on FDA data notes that Rybelsus oral semaglutide tablets in 3, 7, and 14 milligram strengths are classified as to be discontinued as of June 4, 2026, with new Ozempic oral tablets in 1.5, 4, and 9 milligram strengths taking their place. The analysis also reports that most GLP-1 injection shortages, including semaglutide and tirzepatide products, have eased across the U.S. market. (2026-11-02)
What this means for you: If you take Rybelsus or were planning to start it, you are likely to be switched to the new Ozempic tablets and will need to convert your dose and possibly repeat prior authorization paperwork. With injectable shortages mostly resolved, your focus should be on confirming which oral or injectable products your plan now prefers and making sure any switch keeps your dosing and monitoring consistent.
Source: Metabolic Ledger
Related on Metabolic Ledger: /cost/glp1-drug-shortage-guide